Skip to main content
eScholarship
Open Access Publications from the University of California

UC San Diego

UC San Diego Previously Published Works bannerUC San Diego

Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort.

  • Author(s): Parker, Ben
  • Urowitz, Murray B
  • Gladman, Dafna D
  • Lunt, Mark
  • Donn, Rachelle
  • Bae, Sang-Cheol
  • Sanchez-Guerrero, Jorge
  • Romero-Diaz, Juanita
  • Gordon, Caroline
  • Wallace, Daniel J
  • Clarke, Ann E
  • Bernatsky, Sasha
  • Ginzler, Ellen M
  • Isenberg, David A
  • Rahman, Anisur
  • Merrill, Joan T
  • Alarcón, Graciela S
  • Fessler, Barri J
  • Fortin, Paul R
  • Hanly, John G
  • Petri, Michelle
  • Steinsson, Kristjan
  • Dooley, Mary Anne
  • Manzi, Susan
  • Khamashta, Munther A
  • Ramsey-Goldman, Rosalind
  • Zoma, Asad A
  • Sturfelt, Gunnar K
  • Nived, Ola
  • Aranow, Cynthia
  • Mackay, Meggan
  • Ramos-Casals, Manuel
  • van Vollenhoven, Ronald F
  • Kalunian, Kenneth C
  • Ruiz-Irastorza, Guillermo
  • Lim, S Sam
  • Kamen, Diane L
  • Peschken, Christine A
  • Inanc, Murat
  • Bruce, Ian N
  • et al.
Abstract

BACKGROUND:The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE. METHODS:Recently diagnosed (<15 months) patients with SLE from 30 centres across 11 countries were enrolled into the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort from 2000 onwards. Baseline and annual assessments recorded clinical, laboratory and therapeutic data. A longitudinal analysis of factors associated with MetS in the first 2 years of follow-up was performed using random effects logistic regression. RESULTS:We studied 1150 patients with a mean (SD) age of 34.9 (13.6) years and disease duration at enrolment of 24.2 (18.0) weeks. In those with complete data, MetS prevalence was 38.2% at enrolment, 34.8% at year 1 and 35.4% at year 2. In a multivariable random effects model that included data from all visits, prior MetS status, baseline renal disease, SLICC Damage Index >1, higher disease activity, increasing age and Hispanic or Black African race/ethnicity were independently associated with MetS over the first 2 years of follow-up in the cohort. CONCLUSIONS:MetS is a persistent phenotype in a significant proportion of patients with SLE. Renal lupus, active inflammatory disease and damage are SLE-related factors that drive MetS development while antimalarial agents appear to be protective from early in the disease course.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View